Evidence map›Paper›PMID 42631334›Full record

ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026

Safety and Efficacy of Amotosalen-Ultraviolet A Pathogen-Reduced Platelets Transfused to Neonates.

Michael Daskalakis, Linda Sutter-Hyseni, Olaf Ahrens, Andreas Wicki, Vijay Pasapula, Stanley Bentow, Laurence Corash, Johannes Irsch, Jane McDougall, Behrouz Mansouri-Taleghani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michael DaskalakisDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Linda Sutter-HyseniDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Olaf AhrensDivision of Neonatology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Andreas WickiInterregional Blood Donation, Swiss Red Cross, Bern, Switzerland.
Vijay PasapulaCerus Corporation, Concord, CA, USA.
Stanley BentowCerus Corporation, Concord, CA, USA.
Laurence CorashCerus Corporation, Concord, CA, USA.
Johannes IrschCerus Corporation, Concord, CA, USA.
Jane McDougallDivision of Neonatology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Behrouz Mansouri-TaleghaniDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The objective of this study was to compare the efficacy and safety of amotosalen/ultraviolet A pathogen-reduced platelet components (PRPCs) with conventional platelets for transfusion of term and preterm neonates who are vulnerable to transfusion-transmitted infections and transfusion associated graft vs. host disease. Safety and efficacy of concomitant use of PRPC and phototherapy (PT) treatment with a specific focus on a large cohort of premature neonates have not been investigated before. Methods: In this retrospective cohort study, medical records were audited for gestational age, birth weight, number of transfusions, platelet count and transfusion increments, maximum bilirubin, PT, and transfusion-related adverse events. Term and preterm neonates were transfused with conventional PC (CPC) during a period of 72 months (2005-2010) before PRPC and during 57 months after PRPC implementation (2011-2015). Fresh frozen plasma (FFP) and red blood cells (RBCs) were used as surrogate hemostasis indicators. Results: In the first cohort, 92 neonates received 180 CPC and in the second cohort 99 neonates received 225 PRPC. Similar proportions of patients in each cohort had bleeding (central nervous system 18% vs. 19%, pulmonary 3.0% vs. 3.3%). The gestational ages and birth weights were similar (33.1 vs. 33.0 weeks and 1.8 kg for both). The proportion of multiple births (twins, triplets) was significantly higher in the PRPC cohort (27 vs. 6). Neonates treated with PRPC received more concomitant PT treatments (3.8 vs. 2.4). There were no differences in PC, FFP, or RBC units transfused. Mean platelet count increments were not different (PRPC: 82.9 ± 45.1 vs. CPC: 95.9 ± 53.0). No patients had transfusion-related phototoxicity. Conclusion: The study demonstrated PRPC efficacy and safety for term and preterm neonates with or without concurrent PT.

Indexed as

Neonate patientsPathogen reductionPhototherapyPlatelet transfusionPreterm neonates

Identifiers

PMID42631334
PMCPMC13498329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.